Understanding the Stages of Thyroid Cancer
Thyroid cancer staging helps doctors determine the best treatment and predict the likely outcome. It uses the American Joint Committee on Cancer (AJCC)'s TNM system, which assesses tumor size, lymph node involvement, and metastasis.
Staging differs among the main types of thyroid cancer, including medullary, follicular, papillary, and anaplastic.
Anaplastic thyroid cancer is aggressive and is always stage IV. Early stage cancers generally have better treatment outcomes and survival rates.
The American Cancer Society estimates that about 43,800 people in the United States will be diagnosed with thyroid cancer by the end of 2022. Women are affected three times more often than men.
Doctors stage thyroid cancer from stage I to stage IV depending on how far along your cancer has progressed. Different staging systems are used for different types of thyroid cancer.
Keep reading to learn more about how the most common types of thyroid cancer are staged.
How is the staging for thyroid cancer determined?
Thyroid cancer is most often staged using the American Joint Committee on Cancer (AJCC) TNM staging system. This staging system considers:
T: How big the tumor is and whether it has spread to nearby tissues.
N: Whether the cancer has spread into nearby lymph nodes.
M: Whether the cancer has metastasized, meaning spread to distant tissues.
The AJCC staging system differs depending on which type of thyroid cancer you have. The four main types are:
Medullary thyroid cancer: Develops in special cells called C cells that produce the hormone calcitonin.
Follicular thyroid cancer: A usually slow-growing cancer that develops in follicular cells. These cells produce and secrete triiodothyronine (T3) and thyroxine (T4).
Papillary thyroid cancer: Develops in follicular cells and makes up 80% to 85% of thyroid cancers. It generally has the best outlook.
Anaplastic thyroid cancer: Makes up less than 2% of thyroid cancers but is the most aggressive type. It develops in follicular cells.
Knowing which stage you're in helps doctors figure out what the best treatment option may be. It can also give you and your healthcare team the best idea of what to expect in terms of life expectancy and chances of being cured.
Staging for medullary thyroid cancer
The overall 5-year relative survival rate for medullary thyroid cancer is nearly 100% if it's limited to your thyroid and 89% for all stages combined. The 5-year relative survival rate is a measure of how many people with the cancer are alive 5 years later compared to people without the cancer.
Here's a look at the AJCC's TNM system for medullary thyroid cancer:
Stage TNM groups Description
I T1
N0
M0 T1: The cancer is smaller than 0.8 inches across and only found in the thyroid.
N0: It has not spread to nearby lymph nodes.
M0: It has not spread to distant body parts.
II T2
N0
M0 T2: The cancer is bigger than 0.8 inches but smaller than 1.6 inches across. It's only found in the thyroid.
N0: It has not spread to nearby lymph nodes.
M0: It has not spread to distant body parts.
OR
II T3
N0
M0 T3: The cancer is larger than 1.6 inches across and is limited to the thyroid or has grown outside the thyroid but hasn't spread to nearby tissues.
N0: It has not spread to nearby lymph nodes.
M0: It has not spread to distant body parts.
III T1, T2, or T3
N1a
M0 T1 to T3: The cancer can be any size but hasn't invaded tissues around your thyroid.
N1a: The cancer has spread to lymph nodes in your neck.
M0: The cancer hasn't spread to any distant body parts.
IVA T4a
Any N
M0 T4a: The cancer is any size and has grown into nearby tissues such as your windpipe or voice box.
Any N: It may or may not have spread to nearby lymph nodes.
M0: It hasn't spread to distant body parts.
OR
IVA T1, T2, or T3
N1b
M0 T1 to T3: The cancer is any size and may have grown outside the thyroid. It hasn't grown into any nearby structures.
N1b: The cancer has spread to lymph nodes in your neck.
M0: The cancer has not spread to distant body parts.
IVB T4b
Any N
M0 T4b: The cancer is any size and has either grown toward your spine or into major blood vessels nearby.
Any N: The cancer may or may not have spread to lymph nodes.
M0: The cancer has not spread to distant body parts.
IVC Any T
Any N
M1 Any T: The cancer is any size and may have grown into nearby structures.
Any N: The cancer may or may not have spread into lymph nodes.
M1: The cancer has spread into distant areas such as your liver, brain, or bone.
Staging for differentiated (papillary and follicular) thyroid cancer
Staging for papillary or follicular thyroid cancer depends on whether you're over or under the age of 55. The overall 5-year relative survival rate for people with papillary thyroid cancer is nearly 100% and about 98% for follicular cancer.
Stage Age of diagnos is TNM groups Description
I younger than 55 years Any T
Any N
M0 Any T: The cancer is any size.
Any N: The cancer may or may not have spread to lymph nodes.
MO: It hasn't spread to distant areas.
OR
I 55 years or older T1
N0 or NX
M0 T1: The cancer is smaller than 0.8 inches across and is only found in your thyroid gland.
N0 or NX: The cancer hasn't spread to nearby lymph nodes or there isn't enough information to assess if the cancer has spread to lymph nodes.
M0: The cancer hasn't spread to distant areas.
OR
I 55 years or older T2
N0 or NX
M0 T2: The cancer is larger than 0.8 inches across but smaller than 1.6 inches. It's limited to your thyroid.
N0 or NX: The cancer hasn't spread to nearby lymph nodes or there isn't enough information to assess if the cancer has spread to lymph nodes.
M0: The cancer hasn't spread to distant areas.
II younger than 55 years Any T
Any N
M1 Any T: The cancer is any size.
Any N: The cancer may or may not have spread to nearby lymph nodes.
M1: The cancer has spread to distant body parts like your bone or internal organs.
OR
II 55 years or older T1
N1
M0 T1: The cancer is smaller than 0.8 inches across and limited to the thyroid.
N1: The cancer has spread to nearby lymph nodes.
M0: The cancer hasn't spread to distant areas.
OR
II 55 years or older T2
N1
M0 T2: The cancer is larger than 0.8 inches across but smaller than 1.6 inches. It's limited to your thyroid.
N1: The cancer has spread to nearby lymph nodes.
M0: The cancer hasn't spread to nearby areas.
OR
II 55 years or older T3a or T3b
Any N
M0 T3a or T3b: The cancer is larger than 1.6 inches across but limited to the thyroid or the muscles that support your thyroid.
Any N: The cancer may or may not have spread into nearby lymph nodes.
M0: The cancer hasn't spread to distant sites.
III 55 years or older T4a
Any N
M0 T4a: The cancer is any size and has grown beyond your thyroid into surrounding tissues such as your voice box or windpipe.
Any N: The cancer may or may not have spread into nearby lymph nodes.
M0: The cancer hasn't spread to distant sites.
IVA 55 years or older T4b
Any N
M0 T4b: The cancer has spread extensively beyond your thyroid toward your spine or into large blood vessels in the surrounding area.
Any N: The cancer may or may not have spread into nearby lymph nodes.
M0: The cancer has not spread to distant locations.
IVB 55 years or older Any T
Any N
M1 Any T: The cancer is any size.
Any N: The cancer may or may not have spread to nearby lymph nodes.
M1: The cancer has spread to distant parts of your body.
Staging for undifferentiated (anaplastic) thyroid cancer
Anaplastic cancer has the poorest outlook of any thyroid cancer. Its 5-year relative survival rate is 7%. All anaplastic cancers are considered to be stage IV. It's divided into substages depending on its features.
Stage Stage grouping Description
IVA T1, T2 or T3a
N0 or NX
M0 T1, T2, or T3a: The cancer can be any size as long as it's contained to your thyroid.
N0 or NX: The cancer hasn't spread to nearby lymph nodes or there's not enough information to know if it has.
M0: The cancer has not spread to distant parts of your body.
IVB T1, T2 or T3a
N1
M0 T1, T2, or T3a: The cancer can be any size as long as it's contained to your thyroid.
N1: The cancer has spread to nearby lymph nodes.
M0: The cancer has not spread to distant parts of your body.
OR
IVB T3b
Any N
M0 T3b: The cancer is any size and has grown into the muscles that support your thyroid.
Any N: The cancer may or may not have spread into nearby lymph nodes.
M0: The cancer has not spread to distant parts of your body.
OR
T4
Any N
M0 T4: The cancer has grown beyond the thyroid gland and into nearby tissue such as your voice box or windpipe. It also may have grown toward your spine or large blood vessels nearby.
Any N: The cancer may or may not have spread to nearby lymph nodes.
M0: The cancer has not spread to distant parts of your body.
IVC Any T
Any N
M1 Any T: The cancer can be any size.
Any N: The cancer may or may not have spread to nearby lymph nodes.
M1: The cancer has spread into distant body parts such as your bones or internal organs.
Takeaway
Thyroid cancer is broken into stages depending on how far the cancer has progressed. The AJCC's TNM staging for papillary or follicular thyroid cancer also considers your age.
Cancers in early stages are considered easier to treat and have a better outlook. Due to the aggressive nature of anaplastic thyroid cancer, it's always considered stage IV.
Knowing what stage of cancer you're in helps doctors understand how to best manage your cancer. It can also give you an idea of your chances of survival. Survival statistics are often based on old data, so your chances of survival might be better than statistics suggest.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
17 minutes ago
- New York Post
What to know about disease more likely to affect men in light of Deion Sanders' health battle
Colorado football coach Deion Sanders was diagnosed with an aggressive form of bladder cancer earlier this year, had surgery to remove the organ and is now considered cured by his doctors, the Pro Football Hall of Famer said Monday. Sanders said he is upbeat and plans to coach the Buffaloes this fall. Bladder cancer is the 10th leading cause of cancer death in the United States. But recent advancements in its treatment have improved outcomes for people who are diagnosed, according to the American Cancer Society. 5 Deion Sanders was diagnosed with an aggressive form of bladder cancer. AP 5 Bladder cancer is the 10th leading cause of cancer death in the United States. kenchiro168 – The 57-year-old Sanders shared the details of his diagnosis and treatment, which involved surgeons reconstructing a section of his intestine to function as a bladder, and said it 'was a fight, but we made it.' Here's what you should know about bladder cancer. What is bladder cancer? This cancer starts when the cells in the bladder, which stores urine, grow out of control and form tumors. In some cases, the cancer spreads to other parts of the body. The most common symptom for bladder cancer is blood in the urine, which can cause urine to look orange, pink, or rarely, dark red. The color change can come and go, the American Cancer Society says, and early tumors may not cause pain. Pain or burning while urinating, weak stream, frequent urination or urge to go when the bladder isn't full can also be signs of bladder cancer. Symptoms of advanced bladder cancer can include an inability to urinate, bone pain, loss of appetite, weakness, swollen feet and lower back pain on one side. If you have symptoms, it is worth getting checked out, because all of those symptoms might be from other health issues. Blood in the urine is most often from an infection, a benign tumor, a kidney stone or bladder stone or other benign kidney disease, the American Cancer Society said. 5 This cancer starts when the cells in the bladder, which stores urine, grow out of control and form tumors. In some cases, the cancer spreads to other parts of the body. AP 5 Pain or burning while urinating, weak stream, frequent urination or urge to go when the bladder isn't full can also be signs of bladder cancer. eddows – Sanders said during a news conference on Monday that the cancer was found when he went for a precautionary annual CT scan; he has a history of blood clots in his legs. How common is bladder cancer? Bladder cancer is more common in men than women. The American Cancer Society estimates there will be nearly 85,000 new cases in 2025, with more than 65,000 in men. The incidence rate for bladder cancer has decreased by 1% per year in recent years. Death rates have stayed relatively stable, declining by 1% per year since 2013. 5 The American Cancer Society estimates there will be nearly 85,000 new cases in 2025, with more than 65,000 in men. MrAshi – What can cause bladder cancer? Smoking is the biggest risk factor, the American Cancer Society said. The recent decline in incidence rates are likely due to fewer people smoking. Other risk factors include working in jobs that expose you to chemicals — like painters, metal and leather workers, miners and firefighters. People who use a urinary catheter for a long time are also at higher risk. Every morning, the NY POSTcast offers a deep dive into the headlines with the Post's signature mix of politics, business, pop culture, true crime and everything in between. Subscribe here! What is the outlook for bladder cancer patients? Outcomes for bladder cancer patients improve based on if and how much the cancer has spread. The five-year relative survival rate is 72% to 97% if the cancer has not spread outside the bladder, but drops to 40% if the cancer has spread to lymph nodes or other nearby parts of the body, and 9% if it has spread further. Treatment can include surgery to remove the tumor, parts of the bladder or the whole bladder; radiation; chemotherapy; targeted drug therapy and immunotherapy. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Medscape
an hour ago
- Medscape
HS Tied to Higher Risk for Depression and Anxiety
TOPLINE: Patients with hidradenitis suppurativa (HS) showed a 69% higher risk for new-onset depression and a 48% higher risk for new-onset anxiety than individuals without HS, irrespective of disease severity. METHODOLOGY: To address whether HS severity is an independent risk factor for new-onset depression and anxiety, researchers conducted a study from 1997 to 2022 that included 10,206 Danish patients (mean age, 38 years) with hospital-diagnosed HS, matched for age and sex 1:4 with 40,125 individuals without HS (mean age, 37.9 years) from national registries. Primary outcomes were a first diagnosis of depression or anxiety. Researchers also assessed recurrent depression and anxiety in participants with prior diagnoses using a separate analytic subset and a 3-year washout period and disease severity by treatments received and number of hospitalizations for HS-related surgical procedures. Of the patients with HS, 25.9% received no treatment, 12.0% received only topical therapy, 55.5% received systemic nonbiologic treatment, and 6.5% received biologic therapy. In terms of surgical severity, 58.1% of patients had no hospitalizations for HS-related surgery, 18.8% were hospitalized once for surgery, 7.6% were hospitalized twice, and 15.5% had three or more hospitalizations. TAKEAWAY: During follow-up, the incidence rate of new-onset depression or anxiety was 3.11 per 100 person-years among patients with HS vs 1.77 per 100 person-years in the control group; patients with HS had a significantly higher risk for new-onset depression (hazard ratio [HR], 1.69; P < .001) and new-onset anxiety (HR, 1.48; P < .001). The risk of new-onset depression or anxiety remained elevated across all treatment groups, with HRs of 1.62 (P < .001) for topical therapy, 1.61 (P < .001) for systemic nonbiologics, and 1.38 (P < .05) for biologics. No consistent trend in risk was observed across levels of surgical severity; adjusted HR of 1.44 (95% CI, 1.36-1.53) for zero hospitalizations for an HS-related surgical procedure, 1.66 (95% CI, 1.53-2.17) for one, 1.59 (95% CI, 1.33-1.90) for two, and 1.60 (95% CI, 1.40-1.85) for three or more hospitalizations (P < .001 for all). Despite a higher baseline prevalence of prior depression (7.0% vs 0.3%; P < .001) and anxiety (5.9% vs 0.5%; P < .001) among patients with HS than those in the control group, the risk for recurrence was not significantly elevated when compared with the control group. IN PRACTICE: 'This finding emphasizes that depression and anxiety may occur independent of disease severity, and clinicians should be aware of mental disorders across all severity stages and approach these patients in a multidisciplinary setting,' the study authors wrote. They called for research 'to identify other factors that may be associated with the risk of the development of depression and anxiety for this group of patients.' SOURCE: This study was led by Nikolaj Holgersen, MD, Department of Dermato-Venereology & Wound Healing Centre, Copenhagen University Hospital, Copenhagen, Denmark, and was published online on July 30 in JAMA Dermatology. LIMITATIONS: This study relied on hospital diagnoses and contacts for HS, potentially excluding milder cases managed in primary care settings. Using treatment categories as severity proxies could have introduced misclassification bias, and the inclusion of only Danish patients limited generalizability to other populations. DISCLOSURES: The authors did not report funding information. Several authors reported receiving personal fees, grants, advisory fees, and speaker fees from AbbVie, Almirall, Leo Pharma, Novartis, Sanofi, UCB, Pfizer, Sanofi, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation. Two authors are employees of Leo Pharma. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Forbes
2 hours ago
- Forbes
Forget Screen Time, This Is The True Threat To Gen Alpha
CEOs and founders are finally beginning to pay attention to the mobility-gap in our youth. While all eyes are on mobile phones as the greatest threat to our youth's wellbeing, a bigger threat to childhood might be unfolding just beyond the glow of those screens. Across the globe, we're raising a generation that is less physically active, less mobile, and less confident in their bodies than ever before. In the United States, only 20-28% of kids between ages 6 and 17 meet the CDC's recommendation of 60 minutes of daily physical activity. Globally, the situation is even more dire, with over 80% of adolescents not getting enough exercise, according to the World Health Organization. Despite decades of awareness campaigns, public investment, and school initiatives, the needle has barely moved. The consequences ripple out beyond rising obesity or declining cardiovascular health. Lower levels of childhood movement are linked to decreased executive function, poorer mental health, reduced school performance, and higher rates of social isolation. In short, we're quietly undermining an entire generation that will soon find itself struggling not only with their physical well-being, but with the confidence and competence that comes from mastering their own bodies, all in the era of AI that is already making it more difficult for humans to compete. This is why we need to look beyond our concerns over the screen, and examine how we can push and pull our youth to action again. And in this endeavor, companies and their leadership have much more work to do than you might initially think. We Need to Pull Kids Toward Movement, Not Push Them Away From Screens If we want to raise kids who move, we need to build environments that make movement feel rewarding, natural, and most of all, fun. It is not enough to tell children to go outside or scold them for spending too much time online. The same goes for simply taking away their cellphones, even if Jonathan Haidt has made a wonderful case for doing so. Instead, we need to offer meaningful incentives that meet them, and move them, where they are. That's the idea behind WeWard, a free mobile app that turns walking into a rewarding experience. 'When we gamify movement, teenagers suddenly care,' says Yves Benchimol, WeWard's founder and CEO in an interview. 'Across our user base, daily movement jumps by 24 percent once rewards kick in.' Clearly the carrot approach is working, given how one of WeWard's fastest-growing user segments has been among teens and young adults who never saw themselves as 'active.' According to Benchimol, 'The magic doesn't come from collecting points or the gamification alone. The social proof of it all is incredibly important as well. When you're competing with your friends and building healthier habits through community, that's a powerful shift in mindset.' He's particularly passionate about closing mobility equity gaps with methods that pull, instead of push, and he also reminds us of the importance of access to options to move. 'There's a turbo fitness culture these days that promotes rigid diets and expensive workout routines that not everyone can afford,' Benchimol says. 'A healthy lifestyle is something that everyone should have access to in a way that isn't intimidating or extreme. That's why we chose to focus on walking—it's a simple but powerful movement that's incredibly overlooked. Educating the youth on these benefits will be key to wellness reform' What Benchimol is highlighting ties to a growing trend where treating physical activity not as a personal virtue, but as a public good that needs private solutions and education to play a larger role. If we want more movement, we need to design for it on all sides of the economy. That includes smart incentives, but also the resources and tools to make movement easy. Make Mobility Accessible, And The Rest Takes Care of Itself Kids find the joy in mobility early, if only we allow it. For many kids, a love of motion starts the moment they ride their first bike. But fewer and fewer are reaching that milestone, in large part given that we simply don't have access to spaces, or equipment to move the way previous generations did. Perhaps the most striking statistic comes from something as simple as riding a bike. According to Strider Bikes founder Ryan McFarland during our interview, 'Only about a quarter of kids in the U.S. can ride a bike by the time they're six. We used to take it for granted. Now, it's the exception.' Seeing these statistics play out firsthand is part of the reason McFarland created the Strider balance bike to begin with. After watching his own son struggle on traditional learn-to-ride toys that were too cumbersome and complicated, he crafted his own pedal-less starter bike designed to teach balance and confidence before introducing propulsion. 'Balance first, propulsion later. The moment a toddler glides, you've banked a lifetime of confidence,' McFarland says. Recognizing the challenge accessibility poses, McFarland has pushed the company to do more than simply build bikes. The Strider Education Foundation helped launch and now supports All Kids Bike, a nonprofit initiative that puts balance bikes directly into public school kindergarten PE classes. Their turnkey program includes bikes, helmets, curriculum, and teacher training, all funded by donors. 'With over 1,600 active programs in all 50 states, we're reaching 160,000 five-year-olds every year,' says Lisa Weyer, executive director of All Kids Bike. 'And because the equipment lasts up to a decade, we are teaching over 1.6 million kids how to ride.' The appeal to schools is clear: the program fits seamlessly into existing curriculum, doesn't require families to buy their own equipment, and provides measurable outcomes. 'We treat bikes the way we treat books or microscopes,' Weyer explains. 'Bikes shouldn't feel like luxury items. They're essential learning tools and the pathway to a lifetime of mobility.' Both Weyer and McFarland see mobility as a justice issue. 'You don't get to build confidence if you never get the chance to try,' says McFarland. 'That's why we focus on public schools, especially in communities where bikes might be out of reach.' When we break down the barriers of accessibility by removing cost barriers, creating access, and integrating movement into daily routines, kids naturally take to it in ways that show the issue is not due to a lack of interest in movement. Quite the contrary. However, there's another piece of the puzzle: adults modeling the behavior they wan't to see in the youth. Don't Forget Grown-ups Need Play, Too Those who have been around kids know that they model what we do, not what we say. If kids are watching us, and they always are, then they need to see adults enjoying movement, not avoiding it. Given the only race most kids see their parents run is of the rat variety, we have ourselves to blame for much of the lack of movement we see in our progeny. Bringing back movement that is fun to our own lives is an essential starting point that we can't shut our eyes from. And that's where companies like Onewheel come in. 'The idea for Onewheel was inspired by the desire to recreate the feeling of freedom and flow that I first fell in love with growing up snowboarding in the Canadian Rockies,' says Kyle Doerksen, founder of Onewheel, a self-balancing electric board that feels like surfing on land. 'It was never meant to be a toy, but a vehicle that could create a whole new category of sport, and turn the everyday school or coffee run into a micro-adventure.' What began as a Kickstarter project in 2014 has grown into a global community with riders in 139 countries around the world and an active scene of meetups, group rides, and competitions. 'People love to ride together, and we see a lot of parents and older kids who ride together too,' Doerksen adds. 'There's this deep nostalgia for the kind of play we had as kids, exploration, speed, freedom, that I think sometimes we as adults forgot was possible.' The company's latest board is itself a nostalgic nod to the past, the Onewheel XR Classic, a reimagined version of its best-selling board, the discontinued Onewheel XR. Doerksen argues that micromobility is at its core a cultural shift. 'When parents ride to the park instead of driving, when they try and fail and laugh and try again, kids notice. Adults need recess, too.' By making movement aspirational for grown-ups, Onewheel has created a feedback loop: adults who play raise kids who move. And when that loop becomes normal, the next generation doesn't need to be coaxed off the couch. We can't lecture our way out of the youth mobility crisis. What we can do is make moving irresistible. That means more carrots, rewards, recognition, community, and fewer sticks. It means embedding equipment and encouragement where kids already are: schools, parks, city blocks. It means showing them that movement is normal, joyful, and for everyone. Above all, it means treating mobility not as a side effect of good parenting or elite schooling, but as a basic ingredient in a thriving childhood. The bodies of the next generation are already telling us what they need. Our job is to listen, and get them moving.
